Abstract
Seventy-one patients suffering from acute myeloid leukaemia (AML) who were already in complete remission and had already received one further course of cytotoxic drugs as consolidation therapy were randomised to receive maintenance chemotherapy alone or the same maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells. The duration of first remission was slightly, but not significantly, longer in those patients who received immunotherapy. This was true also for the duration of survival after relapse. Comparison with other series suggested that the effect of such immunotherapy on duration of survival after relapse is probably real, but did not clearly indicate whether or not any real difference in the first remission duration existed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Consortia
Rights and permissions
About this article
Cite this article
Medical Research Council. Immunotherapy of acute myeloid leukaemia.. Br J Cancer 37, 1–14 (1978). https://doi.org/10.1038/bjc.1978.1
Issue Date:
DOI: https://doi.org/10.1038/bjc.1978.1
This article is cited by
-
Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects
Klinische Wochenschrift (1983)